Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for DNLI

Stock Name	Denali Therapeutics Inc
Ticker	DNLI(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US24823R1059
LEI	549300ZTQ2HO18L3Q830

Show aggregate DNLI holdings

News associated with DNLI

Financial Survey: Denali Therapeutics (NASDAQ:DNLI) & Celcuity (NASDAQ:CELC): Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Celcuity (NASDAQ:CELC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Analyst Ratings This is a summary of current ratings […] - 2025-09-17 02:12:56
Denali Therapeutics (NASDAQ:DNLI) Receives “Overweight” Rating from Cantor Fitzgerald: Cantor Fitzgerald restated their overweight rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on Monday morning,Benzinga reports. Other research analysts have also recently issued reports about the company. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Morgan Stanley dropped their […] - 2025-09-09 02:50:44
Denali Therapeutics (NASDAQ:DNLI) Upgraded at TD Cowen: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) was upgraded by TD Cowen to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports. DNLI has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research […] - 2025-07-30 02:20:44
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Brokerages: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has received an average rating of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. […] - 2025-07-29 02:30:59
New York State Common Retirement Fund Has $955,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI): New York State Common Retirement Fund decreased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 51.5% in the first quarter, HoldingsChannel reports. The firm owned 70,240 shares of the company’s stock after selling 74,484 shares during the period. New York State Common Retirement Fund’s holdings in Denali Therapeutics were worth $955,000 at […] - 2025-07-25 04:56:54
DekaBank Deutsche Girozentrale Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI): DekaBank Deutsche Girozentrale raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 64,210 shares of the company’s stock after acquiring an additional 4,410 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Denali Therapeutics were worth $935,000 as of its most […] - 2025-07-14 06:44:51
Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts Sells 495,282 Shares: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares […] - 2025-07-14 05:10:49
LABU's Holdings Imply 58% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.71 Average PT from Brokerages: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Buy” from the seventeen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating […] - 2025-06-12 02:28:50
Analysts Anticipate VB To Hit $270: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-09 08:43:39
Two Sigma Advisers LP Acquires Shares of 15,100 Denali Therapeutics Inc. (NASDAQ:DNLI): Two Sigma Advisers LP acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,100 shares of the company’s stock, valued at approximately $308,000. Other hedge funds also recently bought […] - 2025-06-06 05:12:49
Squarepoint Ops LLC Purchases 14,896 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Squarepoint Ops LLC grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,619 shares of the company’s stock after buying an additional 14,896 shares during the quarter. Squarepoint […] - 2025-06-01 05:31:11
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 3,411 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,075 shares of the company’s stock after purchasing an additional 3,411 shares during […] - 2025-05-23 06:26:52
Janus Henderson Group PLC Purchases 7,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Janus Henderson Group PLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,028 shares of the company’s stock after purchasing an additional 7,900 shares during the quarter. Janus Henderson Group PLC’s […] - 2025-05-23 05:26:51
Bank of America Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $27.00: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective reduced by research analysts at Bank of America from $28.00 to $27.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 88.94% from the stock’s current […] - 2025-05-21 02:56:58
Deutsche Bank AG Buys 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Deutsche Bank AG boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 277,853 shares of the company’s stock after purchasing an additional 37,907 shares during the period. Deutsche Bank AG’s holdings in Denali Therapeutics were worth $5,663,000 as of its most […] - 2025-05-19 05:06:53
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Northern Trust Corp: Northern Trust Corp grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,201,518 shares of the company’s stock after acquiring an additional 115,876 shares during the […] - 2025-05-13 05:28:54
Denali Therapeutics (NASDAQ:DNLI) Trading Down 10.1% Following Weak Earnings: Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price was down 10.1% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.41 and last traded at $14.38. Approximately 525,609 shares changed hands during trading, a decline of 52% from the average daily volume of 1,084,610 shares. The stock had previously […] - 2025-05-08 03:08:47
Dimensional Fund Advisors LP Has $37.81 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,855,036 shares of the company’s stock after purchasing an additional 295,594 shares during the period. […] - 2025-05-05 05:20:52
Sterling Capital Management LLC Has $36,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI): Sterling Capital Management LLC raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 589.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,773 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Sterling […] - 2025-04-25 05:34:52
Franklin Resources Inc. Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Franklin Resources Inc. reduced its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,862 shares of the company’s stock after selling 5,179 shares during the period. […] - 2025-04-15 04:56:57
Pictet Asset Management Holding SA Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI): Pictet Asset Management Holding SA raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,356 shares of the company’s stock after buying an additional 2,806 shares during the […] - 2025-04-10 05:37:07
Sei Investments Co. Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI): Sei Investments Co. decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 8.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 24,047 shares of the company’s stock after selling 2,229 shares during the quarter. Sei Investments Co.’s holdings in Denali Therapeutics were worth $490,000 at the end of the […] - 2025-04-10 04:18:49
1,065,608 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Norges Bank: Norges Bank bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,065,608 shares of the company’s stock, valued at approximately $21,717,000. Several other hedge funds also recently made changes to their […] - 2025-04-07 04:51:10
Schroder Investment Management Group Has $5.02 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI): Schroder Investment Management Group increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,800 shares of the company’s stock after purchasing an additional 120,494 shares during the […] - 2025-04-06 05:29:07
Corebridge Financial Inc. Sells 4,665 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Corebridge Financial Inc. lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,800 shares of the company’s stock after selling 4,665 shares during the quarter. […] - 2025-04-04 05:09:15
American Century Companies Inc. Buys 29,155 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): American Century Companies Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 480,529 shares of the company’s stock after buying an additional 29,155 shares during the period. American Century Companies Inc.’s […] - 2025-04-03 04:32:51
Teacher Retirement System of Texas Purchases 5,987 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI): Teacher Retirement System of Texas grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 18.6% in the 4th quarter, Holdings Channel reports. The fund owned 38,178 shares of the company’s stock after buying an additional 5,987 shares during the period. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were […] - 2025-03-31 05:00:58
Cibc World Markets Corp Purchases Shares of 11,633 Denali Therapeutics Inc. (NASDAQ:DNLI): Cibc World Markets Corp acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,633 shares of the company’s stock, valued at approximately $237,000. Other large investors have also modified their holdings […] - 2025-03-26 06:09:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-03-26 04:26:42

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) DNLI holdings

Date	Number of DNLI Shares Held	Base Market Value of DNLI Shares	Local Market Value of DNLI Shares	Change in DNLI Shares Held	Change in DNLI Base Value	Current Price per DNLI Share Held	Previous Price per DNLI Share Held
2025-11-12 (Wednesday)	94,075	USD 1,648,194	USD 1,648,194	241	USD -1,408	USD 17.52	USD 17.58
2025-11-11 (Tuesday)	93,834	USD 1,649,602	USD 1,649,602	0	USD 185,792	USD 17.58	USD 15.6
2025-11-10 (Monday)	93,834	USD 1,463,810	USD 1,463,810	240	USD 58,028	USD 15.6	USD 15.02
2025-11-07 (Friday)	93,594	USD 1,405,782	USD 1,405,782	0	USD 57,092	USD 15.02	USD 14.41
2025-11-06 (Thursday)	93,594	USD 1,348,690	USD 1,348,690	240	USD -41,351	USD 14.41	USD 14.89
2025-11-05 (Wednesday)	93,354	USD 1,390,041	USD 1,390,041	0	USD -2,801	USD 14.89	USD 14.92
2025-11-04 (Tuesday)	93,354	USD 1,392,842	USD 1,392,842	241	USD -37,374	USD 14.92	USD 15.36
2025-11-03 (Monday)	93,113	USD 1,430,216	USD 1,430,216	0	USD -85,664	USD 15.36	USD 16.28
2025-10-31 (Friday)	93,113	USD 1,515,880	USD 1,515,880	0	USD -9,311	USD 16.28	USD 16.38
2025-10-30 (Thursday)	93,113	USD 1,525,191	USD 1,525,191	1,205	USD 31,686	USD 16.38	USD 16.25
2025-10-29 (Wednesday)	91,908	USD 1,493,505	USD 1,493,505	482	USD -53,423	USD 16.25	USD 16.92
2025-10-28 (Tuesday)	91,426	USD 1,546,928	USD 1,546,928	0	USD 64,913	USD 16.92	USD 16.21
2025-10-27 (Monday)	91,426	USD 1,482,015	USD 1,482,015	0	USD 22,856	USD 16.21	USD 15.96

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of DNLI by Blackrock for IE00BDZVHG35

Show aggregate share trades of DNLI

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 BUY 241 18.700 17.170 17.323 USD 4,175 17.66
2025-11-10 BUY 240 16.555 15.325 15.448 USD 3,708 17.67
2025-11-06 BUY 240 15.100 14.300 14.380 USD 3,451 17.70
2025-11-04 BUY 241 15.290 14.830 14.876 USD 3,585 17.73
2025-10-30 BUY 1,205 16.980 16.000 16.098 USD 19,398 17.76
2025-10-29 BUY 482 16.250 16.980 16.907 USD 8,149 17.77
2025-10-22 SELL -964 15.950 17.260 17.129 USD -16,512 17.82 Profit of 663 on sale
2025-10-20 BUY 482 17.250 17.720 17.673 USD 8,518 17.82
2025-10-17 BUY 1,204 16.660 16.800 16.786 USD 20,210 17.83
2025-10-15 BUY 1,920 16.310 16.430 16.418 USD 31,523 17.84
2025-10-03 BUY 1,694 15.420 15.750 15.717 USD 26,625 17.87
2025-10-02 BUY 242 15.200 15.680 15.632 USD 3,783 17.89
2025-09-30 BUY 484 14.520 14.580 14.574 USD 7,054 17.93
2025-09-26 BUY 484 13.950 14.070 14.058 USD 6,804 17.97
2025-09-25 BUY 484 13.430 13.600 13.583 USD 6,574 18.00
2025-09-18 BUY 251 13.180 13.490 13.459 USD 3,378 18.03
2025-09-17 BUY 756 13.060 13.860 13.780 USD 10,418 18.06
2025-07-17 SELL -500 14.530 15.150 15.088 USD -7,544 18.17 Profit of 1,540 on sale
2025-07-11 SELL -2,000 14.520 15.350 15.267 USD -30,534 18.26 Profit of 5,993 on sale
2025-07-02 BUY 13,805 14.900 15.000 14.990 USD 206,937 18.35
2025-06-25 BUY 500 14.450 14.788 14.754 USD 7,377 18.47
2025-06-20 BUY 1,889 13.890 14.130 14.106 USD 26,646 18.56
2025-06-11 BUY 490 15.190 15.690 15.640 USD 7,664 18.78
2025-06-10 BUY 490 15.260 15.620 15.584 USD 7,636 18.80
2025-06-04 SELL -245 14.420 14.670 14.645 USD -3,588 18.94 Profit of 1,052 on sale
2025-04-23 BUY 244 14.870 15.590 15.518 USD 3,786 20.29
2025-04-10 SELL -1,952 12.500 12.970 12.923 USD -25,226 21.03 Profit of 15,821 on sale
2025-04-08 SELL -244 11.470 12.480 12.379 USD -3,020 21.23 Profit of 2,160 on sale
2025-04-07 SELL -244 11.600 11.870 11.843 USD -2,890 21.34 Profit of 2,318 on sale
2025-04-04 SELL -1,225 11.780 12.630 12.545 USD -15,368 21.46 Profit of 10,916 on sale
2025-04-01 BUY 2,673 12.290 13.670 13.532 USD 36,171 21.66
2025-03-31 SELL -717 13.595 14.390 14.311 USD -10,261 21.76 Profit of 5,340 on sale
2025-03-21 BUY 3,732 14.430 14.640 14.619 USD 54,558 22.34
2025-03-14 SELL -3,632 15.150 15.700 15.645 USD -56,823 22.87 Profit of 26,228 on sale
2025-03-07 SELL -454 16.690 16.970 16.942 USD -7,692 23.42 Profit of 2,943 on sale
2025-03-04 SELL -227 15.950 16.500 16.445 USD -3,733 23.77 Profit of 1,663 on sale
2025-02-25 BUY 454 19.200 20.830 20.667 USD 9,383 24.29
2025-02-19 SELL -226 22.230 22.270 22.266 USD -5,032 24.51 Profit of 508 on sale
2025-02-13 BUY 678 21.310 21.540 21.517 USD 14,589 24.76
2025-02-12 BUY 226 20.820 21.030 21.009 USD 4,748 24.84
2025-02-11 BUY 904 20.580 21.510 21.417 USD 19,361 24.93
2024-12-30 SELL -7,267 20.240 20.510 20.483 USD -148,850 26.03 Profit of 40,297 on sale
2024-11-18 SELL -3,675 24.180 25.350 25.233 USD -92,731 27.61 Profit of 8,722 on sale
2024-11-08 SELL -245 31.350 31.460 31.449 USD -7,705 27.18 Loss of -1,047 on sale
2024-10-21 SELL -245 26.380 27.490 27.379 USD -6,708 0.00 Loss of -6,708 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	BUY	241	18.700	17.170	17.323	USD 4,175	17.66
2025-11-10	BUY	240	16.555	15.325	15.448	USD 3,708	17.67
2025-11-06	BUY	240	15.100	14.300	14.380	USD 3,451	17.70
2025-11-04	BUY	241	15.290	14.830	14.876	USD 3,585	17.73
2025-10-30	BUY	1,205	16.980	16.000	16.098	USD 19,398	17.76
2025-10-29	BUY	482	16.250	16.980	16.907	USD 8,149	17.77
2025-10-22	SELL	-964	15.950	17.260	17.129	USD -16,512	17.82 Profit of 663 on sale
2025-10-20	BUY	482	17.250	17.720	17.673	USD 8,518	17.82
2025-10-17	BUY	1,204	16.660	16.800	16.786	USD 20,210	17.83
2025-10-15	BUY	1,920	16.310	16.430	16.418	USD 31,523	17.84
2025-10-03	BUY	1,694	15.420	15.750	15.717	USD 26,625	17.87
2025-10-02	BUY	242	15.200	15.680	15.632	USD 3,783	17.89
2025-09-30	BUY	484	14.520	14.580	14.574	USD 7,054	17.93
2025-09-26	BUY	484	13.950	14.070	14.058	USD 6,804	17.97
2025-09-25	BUY	484	13.430	13.600	13.583	USD 6,574	18.00
2025-09-18	BUY	251	13.180	13.490	13.459	USD 3,378	18.03
2025-09-17	BUY	756	13.060	13.860	13.780	USD 10,418	18.06
2025-07-17	SELL	-500	14.530	15.150	15.088	USD -7,544	18.17 Profit of 1,540 on sale
2025-07-11	SELL	-2,000	14.520	15.350	15.267	USD -30,534	18.26 Profit of 5,993 on sale
2025-07-02	BUY	13,805	14.900	15.000	14.990	USD 206,937	18.35
2025-06-25	BUY	500	14.450	14.788	14.754	USD 7,377	18.47
2025-06-20	BUY	1,889	13.890	14.130	14.106	USD 26,646	18.56
2025-06-11	BUY	490	15.190	15.690	15.640	USD 7,664	18.78
2025-06-10	BUY	490	15.260	15.620	15.584	USD 7,636	18.80
2025-06-04	SELL	-245	14.420	14.670	14.645	USD -3,588	18.94 Profit of 1,052 on sale
2025-04-23	BUY	244	14.870	15.590	15.518	USD 3,786	20.29
2025-04-10	SELL	-1,952	12.500	12.970	12.923	USD -25,226	21.03 Profit of 15,821 on sale
2025-04-08	SELL	-244	11.470	12.480	12.379	USD -3,020	21.23 Profit of 2,160 on sale
2025-04-07	SELL	-244	11.600	11.870	11.843	USD -2,890	21.34 Profit of 2,318 on sale
2025-04-04	SELL	-1,225	11.780	12.630	12.545	USD -15,368	21.46 Profit of 10,916 on sale
2025-04-01	BUY	2,673	12.290	13.670	13.532	USD 36,171	21.66
2025-03-31	SELL	-717	13.595	14.390	14.311	USD -10,261	21.76 Profit of 5,340 on sale
2025-03-21	BUY	3,732	14.430	14.640	14.619	USD 54,558	22.34
2025-03-14	SELL	-3,632	15.150	15.700	15.645	USD -56,823	22.87 Profit of 26,228 on sale
2025-03-07	SELL	-454	16.690	16.970	16.942	USD -7,692	23.42 Profit of 2,943 on sale
2025-03-04	SELL	-227	15.950	16.500	16.445	USD -3,733	23.77 Profit of 1,663 on sale
2025-02-25	BUY	454	19.200	20.830	20.667	USD 9,383	24.29
2025-02-19	SELL	-226	22.230	22.270	22.266	USD -5,032	24.51 Profit of 508 on sale
2025-02-13	BUY	678	21.310	21.540	21.517	USD 14,589	24.76
2025-02-12	BUY	226	20.820	21.030	21.009	USD 4,748	24.84
2025-02-11	BUY	904	20.580	21.510	21.417	USD 19,361	24.93
2024-12-30	SELL	-7,267	20.240	20.510	20.483	USD -148,850	26.03 Profit of 40,297 on sale
2024-11-18	SELL	-3,675	24.180	25.350	25.233	USD -92,731	27.61 Profit of 8,722 on sale
2024-11-08	SELL	-245	31.350	31.460	31.449	USD -7,705	27.18 Loss of -1,047 on sale
2024-10-21	SELL	-245	26.380	27.490	27.379	USD -6,708	0.00 Loss of -6,708 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of DNLI

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	378,159	1,201	906,799	41.7%
2025-09-18	267,705	7,938	845,210	31.7%
2025-09-17	409,861	700	1,166,910	35.1%
2025-09-16	391,495	300	1,419,697	27.6%
2025-09-15	260,665	0	671,937	38.8%
2025-09-12	206,570	0	814,137	25.4%
2025-09-11	275,762	207	657,649	41.9%
2025-09-10	329,334	0	769,460	42.8%
2025-09-09	309,105	0	685,690	45.1%
2025-09-08	379,188	58	1,067,132	35.5%
2025-09-05	349,059	0	2,670,128	13.1%
2025-09-04	280,937	11,807	555,931	50.5%
2025-09-03	417,113	0	1,357,895	30.7%
2025-09-02	422,885	5,205	3,059,398	13.8%
2025-08-29	549,150	3	991,426	55.4%
2025-08-28	543,279	750	1,001,438	54.2%
2025-08-27	366,427	0	654,686	56.0%
2025-08-26	644,048	0	1,095,696	58.8%
2025-08-25	291,784	0	587,617	49.7%
2025-08-22	312,554	200	1,397,371	22.4%
2025-08-21	399,082	0	875,607	45.6%
2025-08-20	326,184	0	625,317	52.2%
2025-08-19	264,863	0	410,141	64.6%
2025-08-18	309,669	0	516,163	60.0%
2025-08-15	209,560	0	463,256	45.2%
2025-08-14	332,064	232	818,152	40.6%
2025-08-13	524,452	0	992,838	52.8%
2025-08-12	325,318	1,582	713,957	45.6%
2025-08-11	295,585	0	597,428	49.5%
2025-08-08	698,451	0	1,028,935	67.9%
2025-08-07	587,323	0	987,051	59.5%
2025-08-06	756,413	0	1,219,503	62.0%
2025-08-05	416,200	26,598	1,111,990	37.4%
2025-08-04	474,241	500	928,766	51.1%
2025-08-01	365,641	0	787,315	46.4%
2025-07-31	376,072	66	896,403	42.0%
2025-07-30	509,961	8	956,417	53.3%
2025-07-29	282,888	12	622,537	45.4%
2025-07-28	292,351	0	614,152	47.6%
2025-07-25	234,267	0	458,041	51.1%
2025-07-24	289,899	84	723,176	40.1%
2025-07-23	345,904	711	676,129	51.2%
2025-07-22	228,079	98	411,315	55.5%
2025-07-21	237,820	0	416,453	57.1%
2025-07-18	226,511	0	419,959	53.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE